Infectious Disease Unit, Department of Health Sciences, University of Molise, Campobasso, Italy.
Braz J Infect Dis. 2012 May-Jun;16(3):297-9.
In this case, a new possible strategy for treatment of hepatitis C virus (HCV) relapsing patients is described. The target of anti-HCV therapy is sustained viral response, but strategies for improving sustained viral response in relapsing patients would be useful, and ribavirin is crucial for obtaining viral response. Six weeks of induction therapy with ribavirin were used to improve efficacy of standard combined antiviral therapy in a patient relapsing to standard therapy. In the present case, the patient had undergone a retreatment with the same regimen with the exception of the six-week induction period with ribavirin. Use of induction therapy with ribavirin in this case has allowed for a sustained viral response without prolonging the interferon exposure time in retreatment.
在这种情况下，描述了一种新的治疗丙型肝炎病毒 (HCV) 复发患者的可能策略。抗 HCV 治疗的目标是持续病毒应答，但改善复发患者持续病毒应答的策略将是有用的，而利巴韦林对于获得病毒应答至关重要。在标准联合抗病毒治疗复发的患者中，使用利巴韦林诱导治疗 6 周，以提高疗效。在本病例中，患者在使用相同方案进行再次治疗时，除了利巴韦林的 6 周诱导期外。在这种情况下，使用利巴韦林诱导治疗使患者获得了持续病毒应答，而没有延长再次治疗中的干扰素暴露时间。
